Skip to main content

Peer Review reports

From: Safety analysis of romiplostim, eltrombopag, and avatrombopag post-market approval: a pharmacovigilance study based on the FDA Adverse Event Reporting System

Original Submission
3 Dec 2024 Submitted Original manuscript
17 Dec 2024 Author responded Author comments - Wei Zhuang
10 Jan 2025 Reviewed Reviewer Report
22 Jan 2025 Reviewed Reviewer Report
4 Feb 2025 Author responded Author comments - Wei Zhuang
Resubmission - Version 2
17 Dec 2024 Submitted Manuscript version 2
5 Feb 2025 Author responded Author comments - Wei Zhuang
Resubmission - Version 3
5 Feb 2025 Submitted Manuscript version 3
12 Feb 2025 Author responded Author comments - Wei Zhuang
Resubmission - Version 4
12 Feb 2025 Submitted Manuscript version 4
17 Feb 2025 Author responded Author comments - Wei Zhuang
Resubmission - Version 5
17 Feb 2025 Submitted Manuscript version 5
18 Feb 2025 Author responded Author comments - Wei Zhuang
Resubmission - Version 6
18 Feb 2025 Submitted Manuscript version 6
19 Feb 2025 Author responded Author comments - Wei Zhuang
Resubmission - Version 7
19 Feb 2025 Submitted Manuscript version 7
Publishing
19 Feb 2025 Editorially accepted
27 Feb 2025 Article published 10.1186/s40360-025-00873-8

You can find further information about peer review here.

Back to article page